

CURRICULUM VITAE

Christopher Hanyoung Lieu, M.D.
March 2021

PERSONAL DATA**Christopher Hanyoung Lieu, M.D.**

Associate Professor of Medicine
University of Colorado Anschutz Medical Campus
School of Medicine
Department of Medicine
Division of Medical Oncology
Colorectal Medical Oncology and Clinical Research Programs
Mail Stop 8117, 12801 E. 17th Avenue, Room 8126
Aurora, CO 80045
Phone: (303) 724-6390; Fax: (303) 724-3889
E-mail: Christopher.Lieu@cuanschutz.edu

Citizenship: USA

EDUCATION AND TRAINING

1996-2000	Bachelor of Science Biology University of North Carolina – Chapel Hill Chapel Hill, NC
2000-2004	Doctor of Medicine Wake Forest University School of Medicine Winston-Salem, NC
2004-2005	Internship, Internal Medicine University of Colorado Anschutz Medical Campus Suzanne Brandenburg, M.D., Program Director Aurora, CO
2005-2008	Residency, Internal Medicine University of Colorado Anschutz Medical Campus Suzanne Brandenburg, M.D., Program Director Aurora, CO
2008-2011	Fellowship, Medical Oncology University of Texas MD Anderson Cancer Center Robert Wolff, M.D., Program Director Houston, TX

ACADEMIC APPOINTMENTS AND LEADERSHIP POSITIONS

2007-2008	Chief Medical Resident, Department of Internal Medicine University of Colorado Anschutz Medical Campus
2009-2010	Chief Fellow, Division of Cancer Medicine University of Texas MD Anderson Cancer Center
2011-2018	Assistant Professor, Division of Medical Oncology University of Colorado Anschutz Medical Campus

- 2014-Present Director, Colorectal Medical Oncology, Division of Medical Oncology
University of Colorado Anschutz Medical Campus
- 2014-2016 Deputy Director, Cancer Clinical Trials Office
University of Colorado Anschutz Medical Campus
- 2016-2019 Chair, Investigator-Initiated Trials Committee
University of Colorado Cancer Center
- 2016-2019 Deputy Associate Director for Clinical Research
University of Colorado Cancer Center
- 2017-Present Director, Gastrointestinal Medical Oncology
University of Colorado Cancer Center
- 2018-Present Associate Professor, Division of Medical Oncology
University of Colorado Anschutz Medical Campus
- 2019-Present Associate Director for Clinical Research
University of Colorado Cancer Center

HOSPITAL, GOVERNMENT, OR OTHER PROFESSIONAL POSITIONS

- 2011-Present Staff Physician, University of Colorado Hospital, Aurora, CO

CLINICAL ACTIVITIES

- 2011-Present Medical Oncology attending (2 days per week) providing care in the outpatient Phase I and GI Medical Oncology Cancer clinics at the University of Colorado Hospital (UCH). I care for patients with gastrointestinal cancers receiving standard of care therapy or being treated in research trials. I supervise medical students, interns, residents, medical oncology and gynecologic oncology fellows in these clinics.

HONORS, SPECIAL RECOGNITIONS AND AWARDS

- 2006 Excellence in Humanism and Teaching Award
Recipient, Arnold P. Gold Foundation
- 2009 Ruth L. Kirschstein National Research Service Award
Recipient, National Institutes of Health (NIH)
- 2010 Young Investigators Award
Recipient, American Society of Clinical Oncology (ASCO)
- 2011 Merit Award
Recipient, Conquer Cancer Foundation
- 2012 Paul Calabresi Career Development Award for Clinical Oncology (K12)
Recipient, National Institutes of Health (NIH)
- 2012 ASCO/AACR Methods in Clinical Cancer Research
Delegate, ASCO/AACR Educational Workshop

- 2012 Young Investigator Award
Recipient, SWOG
- 2013 Conquer Cancer Foundation Career Development Award
Recipient, American Society of Clinical Oncology (ASCO)
- 2015 Department of Internal Medicine Rising Stars Award
Recipient, University of Colorado Anschutz Medical Campus
- 2017 ASCO Leadership Development Program
- 2017 NCI Cancer Clinical Investigator Team Leadership Award (CCITLA)
- 2019 ASCO Advocacy Champion

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

- 2006-Present Member, Arnold P. Gold Foundation
- 2008-Present Member, American Association for Cancer Research (AACR)
- 2008-Present Member, American Society of Clinical Oncology (ASCO)
- 2012-Present Member, Rocky Mountain Oncology Society (RMOS)
- 2012-Present Member, SWOG

MAJOR COMMITTEES AND SERVICE RESPONSIBILITIES**National Committees/Service**

- 2013-Present Neuroendocrine Cancers
National Comprehensive Cancer Network (NCCN)
Role: Panel Member
- 2013-2017 Colon Cancer Task Force
National Cancer Institute (NCI)
Role: Member, Drug Development Expert
- 2013-Present ARCAD Foundation
Role: Board Member
- 2014-2017 Guideline for Molecular Markers for Colorectal Cancer
ASCP – CAP – AMP – ASCO Working Group
Role: Expert Panel
- 2015-Present Gastrointestinal Translational Medicine Subcommittee
Southwest Oncology Group (SWOG)
Role: Vice-Chair
- 2015-Present Fight Colorectal Cancer Immuno-oncology Working Group
Role: Member
- 2017-Present Colon Cancer Task Force
National Cancer Institute (NCI)
Role: Vice-Chair

- 2017-Present American Society of Clinical Oncology Gastrointestinal Cancers Guideline Advisory Group
American Society of Clinical Oncology (ASCO)
Role: Member
- 2018-Present National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS)
UG3/UH3 Review Committee
Role: Reviewer
- 2018-Present American Society of Clinical Oncology Stage II-III Colon Cancer Guideline Group
American Society of Clinical Oncology (ASCO)
Role: Co-Chair
- 2018-2020 National Cancer Institute (NCI) Moonshot MP2PRT Review Committee
Role: Reviewer
- 2019-Present National Institutes of Health (NIH) Biostatistical Methods and Research Design Study Section
Role: Reviewer
- 2019-Present American Society of Clinical Oncology (ASCO) University Editorial Board
Role: Editorial Board Member
- 2019-Present NCCN Board of Directors
- 2020-Present Member, Oncologic Drugs Advisory Committee (ODAC)
Food and Drug Administration (FDA)

Local Committees/Service

- 2011-2016 Protocol Review and Monitoring Committee
University of Colorado Cancer Center, Aurora, CO
Role: Member
- 2011-Present Internal Medicine Residency Interview Committee
University of Colorado Anschutz Medical Campus, Aurora, CO
Role: Member
- 2011-Present Hematology/Oncology Fellowship Interview Committee
University of Colorado Anschutz Medical Campus, Aurora, CO
Role: Member
- 2012-2015 Chris4Life Colon Cancer Foundation
Role: Scientific Advisory Board Member
- 2012-Present Morbidity and Mortality Task Force Committee
University of Colorado Anschutz Medical Campus, Aurora, CO
Role: Member
- 2016-Present School of Medicine Admissions Committee
University of Colorado Anschutz Medical Campus, Aurora, CO
Role: Member

- 2016-Present Colon Cancer Alliance
Role: Scientific Advisory Board Member
- 2018-Present Golfers Against Cancer and Wings of Hope Grant Application Review Committee
Role: Reviewer

Community Presentations and Service

- 2012 “Advances in the treatment of colorectal cancer”
Colorado Cancer Center Patient and Roundtable Discussion
University of Colorado Anschutz Medical Campus, Aurora, CO
Role: Faculty and Speaker
- 2013-Present Presentation to high school students - “Developmental Therapeutics and Clinical Trials Presentation”
Prairie View High School, Brighton, CO
Role: Faculty and Speaker
- 2014-2015 Scope it Out 5K for Colorectal Cancer
Denver, CO
Role: Co-Chair
- 2015-Present Presentation to high school students - “Cancer History and Clinical Trials Lecture”
Prairie View High School, Brighton, CO
Role: Faculty and Speaker
- 2016-Present Colon Cancer Alliance Undy 5000
Denver, CO
Role: Member, Planning Committee
- 2018-Present Colorectal Cancer Alliance Blue Hope Bash
Denver, CO
Role: Sponsor, Planning Committee

Media and Public Awareness

- 2011 [Checking in with Past YIA Recipient Christopher Lieu, MD](#) – Interview, ASCO Connection
- 2012 DoctorLine9 - KUSA, Denver, CO
- 2012 GI Cancers and Health Concerns - TV News Interview aired on KUSA, Denver, CO
- 2012 [Study Conducted at University of Colorado Cancer Center Finds Sigmoidoscopy Reduces Colorectal Cancer Rates](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2013 [Fifth annual Undy 5000 raises approximately \\$120,000](#) - Colorado Cancer Blogs, University of Colorado Cancer Center
- 2013 [CU Cancer Center Study: Young patients with metastatic colorectal cancer at higher risk](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2013 [Researchers Detail Possible Resistance Mechanisms of Colorectal Cancer to Bevacizumabm \(Avastin\)](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2013 [What long term outcome should early stage colon cancer patients expect?](#) – Interview, ColonCancerAnswers.com
- 2013 [Daily Habits After Chemotherapy for Colorectal Cancer](#) - Interview, ColonCancerAnswers.com
- 2013 [How to Prevent Colon Cancer](#) – Interview, ColonCancerAnswers.com

- 2013 [Lowering the Risk of Recurrence after Chemotherapy](#) – Interview, ColonCancerAnswers.com
- 2013 [Does Chemotherapy Lower the Risk of Recurrence of Colorectal Cancer](#) – Interview, ColonCancerAnswers.com
- 2013 [How Will My Life Change After Chemotherapy for Colorectal Cancer](#) – Interview, ColonCancerAnswers.com
- 2013 [What is the Chris4Life Foundation](#) – Interview, ColonCancerAnswers.com
- 2013 [Advice for newly Diagnosed Colon Cancer Patients](#) – Interview, ColonCancerAnswers.com
- 2013 [Wings of Hope for Pancreatic Cancer Research](#) – Fundraising Benefit
- 2014 [CU Cancer Center reports results of Phase 1 clinical trial of Avastin with immune drug against solid tumors](#) - Colorado Cancer Blogs, University of Colorado Cancer Center
- 2014 [First Annual Scope It Out 5K Raises Colon Cancer Awareness](#) - Colorado Cancer Blogs, University of Colorado Cancer Center
- 2014 [At-Home Test Could help Detect Colon Cancer Earlier](#) – TV News Interview aired on KUSA, Denver, CO
- 2014 [Is a Treatment for Your Cancer Sitting on a Dusty Shelf](#) - Colorado Cancer Blogs, University of Colorado Cancer Center
- 2015 [DNA Test Could Help You Avoid Colonoscopy, Cancer](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2015 [Young Colon Cancer Patient Finds Hope at CU Cancer Center](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2015 [Study Shows Colorectal Cancer Genetically Different in Older and Younger Patients](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2015 [Scope it Out 5K Aims to Beat Colorectal Cancer](#) - Colorado Cancer Blogs, University of Colorado Cancer Center
- 2015 [Processed Meats and Cancer Risk](#) – TV News Interview aired on KUSA, Denver, CO
- 2015 [Soaring incidence of young-onset colorectal cancer raises questions about screening, treatment](#) – Interview, HemeOnc Today
- 2015 [TAK-733 Shows Challenge of Using a Promising Drug in the Human Body](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2015 [Precision medicine and Colorectal Cancer](#) – CRC Webinar, Fight Colorectal Cancer
- 2015 [Know Your Biomarker](#) – Presentation, Amgen, Inc.
- 2016 [What's Driving the Rising Rates of colorectal Cancer in Young Adults: A Conversation with Christopher Lieu, MD](#) – The ASCO Post
- 2016 [Current and Emerging Colorectal Cancer Treatment Options, With Dr. Christopher Lieu, MD](#) – The Colon Cancer Podcast
- 2016 [Novel Therapies beyond Immunotherapy for GI Malignancies](#) – Presentation, ImedexCME
- 2016 [Study Shows Different Genetic Drivers of Colorectal Cancer in Older and Younger Patients](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2016 [Obstacles of Curing Cancer](#) – Colorado Cancer Blogs, University of Colorado Cancer Center

- 2016 [Wnt Stem Cell Signaling Pathway Implicated in Colorectal Cancer in Patients under 50](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2016 [As Colorectal Cancer Rate Falls, Diagnosis of Late-Stage Cancer in Young Patients is Up](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2016 [Biomarkers for Treatment Selection in Colon Cancer](#) – Podcast, Imedex E-Learning
- 2016 [All Hands on Deck](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2017 [In Metastatic Colorectal Cancer, Two Targeted Treatments Better Than One](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2017 [Young Colon Cancer Patient Can Dream About the Future](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2017 [More Colorado millennials have colorectal cancer, new study shows](#) – TV News Interview aired on KDTV, Denver, CO
- 2017 [CCF Career Development Award Recipient Dr. Christopher Lieu Takes on RAS-Mutant Colorectal Cancer](#) – Gastrointestinal Cancers Symposium Daily News
- 2017 [Dr. Lieu to lead committee for investigator-initiated clinical trials](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2017 [Advocates Reveal Cancer Survivorship Challenges and Resources during National Comprehensive Cancer Network's Patient Advocacy Summit](#) – National Comprehensive Cancer Network
- 2018 [CU Cancer clinical trial takes on treatment resistant breast cancer](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2018 [University of Colorado Cancer Center – Ask us anything about colorectal cancer](#) – Facebook Live
- 2018 [Buddy Check9: Cancer research and clinical trials](#) – TV News Interview aired on KUSA, Denver, CO
- 2018 [New study looks at effectiveness of combination therapy against refractory, metastatic colon cancer](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2019 [Leaders meet in Colorado to set research agenda for early-onset colorectal cancer](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2019 [ASCO Guideline Recommends Shorter-Course Adjuvant Chemotherapy for Some Patients With Stage III Colon Cancer](#) – ASCO Post
- 2020 [Less chemotherapy may have more benefit in rectal cancer](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2020 [Technology, Teamwork and Trials Add Up to Top Care](#) – CU Anschutz Today, University of Colorado Denver
- 2020 [Invited Expert Interview: Gastrointestinal Cancer Insights](#) – ASCO Direct Focus
- 2020 [Rectal cancer treatment without surgery](#) – UCHealth Today
- 2020 [Cancer Research in the Time of COVID-19](#) – Colorado Cancer Blogs, University of Colorado Cancer Center
- 2020 [CU doctors hope longtime message of upward trend in colorectal cancer cases gets heard](#) – Colorado Cancer Blogs, University of Colorado Cancer Center

LICENSURE AND BOARD CERTIFICATIONS

2007-2017 Diplomat, Internal Medicine, American Board of Internal Medicine

2007-Present Colorado State Medical License
2007-Present United States DEA
2008-Present Texas State Medical License
2011-2021 Diplomate, Medical Oncology, American Board of Internal Medicine

EDITORIAL REVIEW AND REFEREE WORK

Editorial Board

2016-Present *Oncology Research*
2018-Present *Journal of the National Cancer Institute (JNCI)*
2020-Present *Cancer Treatment and Research Communications*

Ad Hoc Reviewer

2012-Present *Cancer Treatment Reviews*
2012-Present *Investigational New Drugs*
2012-Present *Cancer Chemotherapy and Pharmacology*
2012-Present *Cancer Discovery*
2013-Present *Clinical Cancer Research*
2013-Present Clinical Trial Proposals – NCI Colon Task Force
2013-Present Medical Research Council (MRC), United Kingdom
2013-Present American Society of Clinical Oncology (ASCO)
2014-Present *American Journal of Hematology/Oncology*
2014-Present *Expert Opinion on Drug Discovery*
2014-Present *Colorectal Cancer*
2015-Present *Clinical Colorectal Cancer*
2015-Present *Journal of the National Cancer Institute (JNCI)*
2015-Present *Molecular Cancer Therapeutics*
2016-Present *Journal of the National Comprehensive Cancer Network*
2016-Present *Oncotarget*
2019-Present *New England Journal of Medicine*
2020-Present ASTRO Rectal Cancer Guidelines

INVITED EXTRAMURAL LECTURES, PRESENTATIONS, AND VISITING PROFESSORSHIPS

Invited Lectures: National Meetings

1. Impact of anti-VEGF therapy on cytokines and angiogenic factors in metastatic colorectal cancer. Division of Pediatrics Grand Rounds, University of Texas MD Anderson Cancer Center, Houston, TX, 2010
2. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. Division of Cancer Medicine Grand Rounds, University of Texas MD Anderson Cancer Center, Houston, TX, 2011

3. Medical oncology overview of hepatobiliary carcinoma. Southwest Oncology Group (SWOG) Fall Conference. San Antonio, TX, 2011
4. KRAS Mutant Tumor Types: Strategies to Overcome Challenges in Treatment, CancerNet: Current Strategies in the Treatment of Colorectal Cancer and Non-colorectal Gastrointestinal Cancers. Los Angeles, CA, 2012
5. Metastatic Colorectal Cancer Case Debates: Practical Solutions to Provide Optimal Management. Lawrence Memorial Hospital Oncology Center, Lawrence, KS, 2012
6. Targeting the WNT Pathway for Colorectal Cancer Therapy. NCI Colon Task Force, Chicago, IL, 2014
7. PRIME Rounds in Metastatic Colorectal Cancer. Webcast, 2014
8. Evidence Guiding the Clinical Pathways to Surveillance, Diagnosis, and Treatment of Hepatocellular Carcinoma, Alaska VA Healthcare System. Anchorage, AK, 2015
9. Clinical Trial Database Virtual Round Table Webinar. Chris4Life Colon Cancer Foundation with Smart Patients, Inc., 2015
10. Never Too Young for Colon Cancer; My Story: Colon Cancer Before 50. Colon Cancer Alliance, Washington DC, 2015
11. Know Your Biomarker Webinar, Collaborative Project with Colon Cancer Alliance. Chris4Life Colon Cancer Foundation and Fight Colorectal Cancer, Washington DC, 2015
12. A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer. Conquer Cancer Foundation Scientific and Career Development Retreat, Alexandria, VA, 2015
13. Treatment of Colorectal Cancer in Young Adults. Never Too Young Coalition Webinar, Colon Cancer Alliance, Washington DC, 2016
14. Biomarkers for Colorectal Cancer, Great Debates in GI Malignancies. New York City, NY, 2016
15. Update of Targeted Therapies Beyond Immunotherapy, Great Debates in GI Malignancies, New York City, NY, 2016
16. Latest in CRC; Findings from the 2016 ASCO Annual Meeting. Colon Cancer Alliance Webinar, Washington DC, 2016
17. A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer. NCI-CTEP Early Drug Development Meeting, Bethesda, MD, 2016
18. Live Your Best Life with Metastatic Colorectal Cancer. Colon Cancer Alliance Symposium, Mesa, AZ, 2016
19. Emerging Treatment Opportunities in Neuroendocrine Tumors. National Association of Managed Care Physicians, Las Vegas, NV, 2016
20. Back to the Future: Irinotecan-based combination studies. 2017 ASCO Annual Meeting, Chicago, IL, 2017
21. Biomarkers for Colorectal Cancer, What you need to know, FightCRC Webinar, 2017
22. Emerging Targets in the Treatment of Metastatic Colorectal Cancer, University of Texas MD Anderson Cancer Center, Houston, TX, 2017
23. Fight Colorectal Cancer Collaboration with University of Colorado Cancer Center, National Comprehensive Cancer Network Patient Advocacy Summit, Washington, DC 2017
24. Biomarkers and emerging therapies in the treatment of metastatic colorectal cancer, University of Texas MD Anderson Cancer Center GI Cancer Center Support Grant Series, Houston, TX, 2018
25. mCRC what do I need to know, University of Texas MD Anderson and Colorectal Cancer Alliance National Meeting, Houston, TX 2018
26. The right and left of incorporating targeted therapy into the management of colorectal cancer, 2019 ASCO Annual Meeting, Chicago, IL 2019

27. ctDNA and colorectal cancer: ready for primetime? 17th Annual West Coast Colorectal Cancer Symposium, Seattle, WA, 2019
28. Adjuvant Therapy: when did it get so complex? 2020 ASCO Annual Meeting, Chicago, IL 2020
29. A Specialty Series Review of Targeted Tyrosine Kinase Inhibitors Used for the Management of Advanced Hepatocellular Carcinoma, Live Virtual CME Program, Med Learning Group 2020
30. Managing Risk and Fear of COVID. AllyCon 2020. Washington DC 2020
31. ctDNA Transforms Decision-Making. Ruesch Symposium for the Cure of GI Cancers. Georgetown University, Washington DC 2020
32. ctDNA is ready to direct adjuvant therapy: No. Great Debates in GI Malignancies. 2021

Invited Lectures: Local Meetings

1. Virtual Colonoscopy: Ready for Primetime? Department of Internal Medicine Grand Rounds, University of Colorado Anschutz Medical Campus, Aurora, CO, 2008
2. KRAS Mutant Colorectal Cancer: Strategies to Overcome Challenges in Treatment. University of Colorado Cancer Center Symposium Series, Aurora, CO, 2012
3. The Past, Present, and Future of Cancer Medicine. University of Colorado Internal Medicine Grand Rounds, University of Colorado Anschutz Medical Campus, Aurora, CO, 2013
4. The History of Chemotherapy and Drug Development, University of Colorado Developmental Therapeutics Program Education Symposia, University of Colorado Anschutz Medical Campus, Aurora, CO, 2013
5. Of Mice and Men, Advances in the Treatment of KRAS Mutant Colorectal Cancer. Metro Denver Oncology Nursing Society Research Lecture Series, Denver, CO, 2013
6. From Bench to Bedside: Translational Drug Development in Metastatic Colorectal Cancer. University of Colorado Research and Innovation Conference, Denver, CO, 2014
7. Right to Try. University of Colorado Ethics Grand Rounds, Denver, CO, 2014
8. Right to Try. University of Colorado School of Medicine Ethics Bites, Denver, CO, 2014
9. North American Neuroendocrine Tumor Society (NANETS) Regional Conference Organizing Committee Chairperson, Denver, CO, 2014
10. Advances in the Treatment of Neuroendocrine Cancers. Midwinter Neuroendocrine Conference, Parker, CO, 2015
11. Conversations About Women's Health. University of Colorado Anschutz Medical Campus, Aurora, CO, 2015
12. Precision Medicine and Immunotherapy Webinar. Fight Colorectal Cancer Research Advocacy Training Seminar, Denver, CO, 2015
13. Value-Based Cancer Care. Cancer Clinical Trials Office Education Session, Denver, CO, 2016
14. Update on Prevention and Treatment Strategies for Colorectal Cancer. Mountain States Cancer Conference, Aurora, CO, 2016
15. [Cancer 101: The Past, Present, and Future of Cancer Treatment](#). Let's Talk About Cancer Series, Aurora, CO, 2018

TEACHING AND MENTORSHIP RECORD

CLASSROOM TEACHING

2009-2010	Hematology/Oncology Fellowship Core Curriculum, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
2010-2011	Hematology/Oncology Fellowship Communication Skills Workshop, University of Texas MD Anderson Cancer Center, Houston, TX
2011-Present	Division of Medical Oncology Fellowship Core Curriculum Lecture, "Hepatobiliary Cancers" University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO

- 2011-Present Division of Medical Oncology Fellowship Core Curriculum Lecture, "Oncology Emergencies", University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO
- 2011-Present Department of Medicine, Career/Elective Fair, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO
- 2013-Present Internal Medicine Residency Research Pathway Lecture Series "Interpreting Clinical Trials", University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO
- 2015-Present Lecture, "Best of ASCO: GI Update", University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO
- 2017-Present Lecture, "Clinical Trial 101 and OnCore Introduction", University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO
- 2017-Present Division of Medical Oncology Fellowship Core Curriculum Lecture, "Early-Stage Colorectal Cancer" University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO

MENTORSHIP TEACHING

Clinical Fellows

- 2012-2013 Elizabeth Kessler, M.D. – Medical Oncology fellow; currently Assistant Professor, University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Medical Oncology, Aurora, CO
- 2015-2018 Anna Capasso, M.D. – Developmental Therapeutics Laboratory Fellow, University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Medical Oncology, Aurora, CO (now Assistant Professor, University of Texas Austin Livestrong Cancer Institutes)
- 2016-Present Gentry King, M.D. – Hematology/Oncology fellow; currently Assistant Professor of Medicine, University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Medical Oncology, Aurora, CO
- 2016-2018 Anuradha Krishnamurthy, M.D. – Developmental Therapeutics fellow; currently Assistant Professor of Medicine, University of Pittsburgh, Pittsburgh, PA
- 2018-2020 Gurprataap Sandhu, M.D. – Hematology/Oncology fellow; currently clinical investigator, University of Pittsburgh, Pittsburgh, PA, Department of Medicine, Division of Medical Oncology, Aurora, CO
- 2020-Present Tyler Friedrich, M.D. – Hematology/Oncology fellow, University of Colorado

Clinical Residents

- 2012-2014 Paul Brittain, M.D. - Internal Medicine Resident; currently Hematology/Oncology fellow, University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Medical Oncology, Aurora, CO
- 2013-2016 Aaron Scott, M.D. – Internal Medicine Resident; currently Assistant Professor, University of Arizona, Tucson, AZ
- 2019-Present Meryl Colton, B.A. – Internal Medicine resident; University of Colorado Anschutz Medical Campus, Aurora, CO

Medical Students

- 2015-2018 Oren Gordon, B.A. – medical student; University of Colorado Anschutz Medical Campus, Aurora, CO
- 2016-Present David Sheneman, B.S. – medical student; University of Colorado Anschutz Medical Campus, Aurora, CO
- 2016-2019 Meryl Colton, B.A. – medical student; University of Colorado Anschutz Medical Campus, Aurora, CO

Premedical Students

- 2012-2013 Logan Hostetter, B.S. – premedical student; currently medical student, University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Medical Oncology, Aurora, CO
- 2013 Jordan Wehe – premedical student; currently BA/BS-MD Program, University of Colorado Anschutz Medical Campus, Department of Medicine, Division of Medical Oncology, Aurora, CO

FUNDING: GRANT SUPPORT**FEDERAL****Active**

- Title: Utilizing MEK and VEGF Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy
Sponsor: R01CA229259-01
Role: Principal Investigator
Period: 09/01/2018 – 08/31/2021
Amount: \$590,994
Percent Effort: 2.4 CM
- Title: Southwest Early Clinical Trials Consortium
Sponsor: 1UM1CA186688
Role: Co -Investigator: Christopher H. Lieu, M.D.; Principal Investigator: Wells Messersmith, M.D.
Period: 06/01/2020 – 05/31/2025
Amount: \$ 10,000
Percent Effort: 0.6 CM
- Title: Investigating the role of MEK and non-canonical Wnt inhibition in altering the immune microenvironment in metastatic colorectal cancer
Sponsor: Cancer League of Colorado; AWD-183090-CL
Role: Principal Investigator: Christopher H. Lieu, M.D.
Period: 07/01/2018 – 06/30/2021
Amount: \$60,000
Percent Effort: 0 CM

Completed

- Title: Research Training in Academic Medical Oncology
Sponsor: T32 CA009666
Role: Fellow: Christopher H. Lieu, M.D.; Principal Investigator: Waun Ki Hong, M.D., Co-PI: Robert A. Wolff, M.D.
Period: 07/01/2009 – 06/30/2011
Amount: \$50,000
Percent Effort: 12 CM
- Title: The role of bFGF in the resistance to anti-VEGF therapy in metastatic colorectal cancer
Sponsor: ASCO Cancer Foundation Young Investigators Award
Role: Principal Investigator: Christopher H. Lieu, M.D.
Period: 07/01/2010 – 06/30/2011
Amount: \$50,000
Percent Effort: 9 CM

Title: Paul Calabresi Award in Clinical Oncology Research
Sponsor: National Institutes of Health; NIH K12 5K12 CA086913-11
Role: Clinical Scholar; Christopher H. Lieu, M.D.; Principal Investigator: Madeline Kane, M.D., Ph.D.
Period: 04/2012 – 06/30/2013
Amount: \$130,000
Percent Effort: 9 CM

Title: Discovery of novel targets for young patients with colorectal cancer
Sponsor: Cancer League of Colorado; AWD-132771
Role: Principal Investigator: Christopher H. Lieu, M.D.
Period: 07/01/2013 – 06/30/2015
Amount: \$30,000
Percent Effort: 0 CM

Title: A patient selective randomized phase II trial comparing the novel MEK inhibitor, TAK-733, to standard of care chemotherapy in patients with advanced KRAS mutant colorectal cancer
Sponsor: Conquer Cancer Foundation of ASCO Career Development Award; AWD-130730
Role: Principal Investigator: Christopher H. Lieu, M.D.
Period: 07/01/2013 – 06/30/2016
Amount: \$66,667
Percent Effort: 2 CM

Title: Rational targeting of the MAPK pathway in atypical RAS mutant colorectal cancer in next generation preclinical models
Sponsor: The Hope Foundation SWOG Early Exploration and Development; SEED AWD-152129
Role: Principal Investigator: Christopher H. Lieu, M.D.
Period: 04/01/2015-02/28/2017
Amount: \$60,000
Percent Effort: 0 CM

Title: Development of novel targeted agents for metastatic colorectal cancer
Sponsor: National Institutes of Health; NIH K23 CA190849-01A1
Role: Principal Investigator: Christopher H. Lieu, M.D.
Period: 07/01/2015 – 06/30/2018
Amount: \$158,000
Percent Effort: 9 CM

Title: NCI Cancer Clinical Investigator Team Leadership Award (CCITLA)
Sponsor: National Cancer Institute; P30CA046934
Role: Principal Investigator: Christopher H. Lieu, M.D.
Period: 07/01/2018-06/30/2019
Amount: \$60,000
Percent Effort: 3 CM

14. BIBLIOGRAPHY

Below is a list of the articles and abstract presentations related to my clinical or clinical research activities (for a more comprehensive list please refer to CV or Investigator's Portfolio). My publication metrics (as of July 10, 2020) are:

- Google Scholar citations: 3146
- Google Scholar h-index (largest number h such that h publications have at least h citations): 21
- Google Scholar i10-index (number of publications with at least 10 citations): 41

List of Publications**Original Research: Peer-Reviewed**

1. **Lieu C**, Janssen WJ, Saint S, Dhaliwal G. The tip of the iceberg. *J Hosp Med* 2009; 4(5):317-20. PMID: 19504498
2. O'Bryant C, **Lieu C**, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. *Cancer Chemother Pharmacol* 2009; 63(3):477-89. PMID: [18509645](#)
3. **Lieu C**, Chow L, Pierson A, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. *Invest New Drugs* 2009; 27(1):53-62. PMID: [18618082](#)
4. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Adinin R, Overman MJ, Valero V, Wen S, **Lieu C**, Yan S, Tran HT, Ellis L, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. *J Clin Oncol* 2010; 28(3):453-9. PMID: [20008624](#)
5. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, **Lieu CH**, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. *Cancer* 2011; 117(20):4623-32. PMID: [21456008](#)
6. **Lieu CH**, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. *Ann Oncol* 2011; 23(3): 652-8. PMID: [21653683](#)
7. **Lieu CH**, Tan AC, Leong S, Diamond JR, Eckhardt SG. From Bench to Bedside: Examples of lessons learned in the translation of preclinical studies of targeted agents in cancer drug development. *J Nat Cancer Inst* 2013; 105(19): 1441-56. PMID: [24052618](#)
8. **Lieu CH**, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. *PLOS ONE* 2013; 8(10):e77117. PMID: [24143206](#)
9. **Lieu CH**, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Goldberg RM, Sargent D, Eckhardt SG, Eng, C. The association of age with survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program. *J Clin Oncol* 2014; 32(27): 2975-84. PMID [25002720](#)
10. Chen ZY, Raghav K, **Lieu CH**, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Quao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. *Br J Cancer* 2015; doi. 10.1038/bjc.2015.61 [epub ahead of print]. PMID [25688736](#)
11. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, **Lieu CH**, McManus M, Tan AC, Zheng X, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt SG, Messersmith WA. A NOTCH1 Gene Copy Number Gain is a Prognostic Indicator of Worse Survival and a Predictive Biomarker to a Notch1 Targeting Antibody in Colorectal Cancer. *Int J Cancer* 2015; 138(1): 195-205. PMID: [26152787](#)
12. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkiwsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, **Lieu C**, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D; National comprehensive cancer network. Neuroendocrine Tumors, version 1.2015. *J Natl Compr Canc Netw* 2015; 13(1): 78-108. PMID: [25583772](#)
13. **Lieu CH**, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG. Antitumor activity of a potent MEK inhibitor, TAK-733, against

- colorectal cancer cell lines and patient derived xenografts. *Oncotarget* 2015. doi: 10.18632/oncotarget.5949 [PMID: 26439693](#)
14. Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapareddy S, Weekes C, Spratlin J, **Lieu CH**, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. *Invest New Drugs*. 2015 Dec 30. [PMID: 26715573](#)
 15. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, **Lieu CH**, Kim GP, Want Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. *Mol Cancer Ther* 2016; 15(3):439-47. [PMID: 26823490](#)
 16. Meguid C, Schulick RD, Schefter TE, **Lieu CH**, Boniface M, Williams N, Vogel JD, Gajdos C, McCarter M, Edil BH. The Multidisciplinary Approach to GI Cancer Results in Change of Diagnosis and Management of Patients. Multidisciplinary Care Impacts Diagnosis and Management of Patients. *Ann Surg Onc* 2016; doi: 10.1245/s10434-016-5343-8. [PMID: 27342825](#)
 17. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, **Lieu C**, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis Jm Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *J Clin Oncol* 2017. doi: 10.1200/JCO.2016.71.9807. [PMID: 28165299](#)
 18. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, **Lieu C**, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis Jm Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *AM J Clin Pathol* 2017. doi: 10.1093/ajcp/aqw209. [PMID: 28165529](#)
 19. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, **Lieu C**, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis Jm Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *J Mol Diagn* 2017. doi: 10.1016/j.jmoldx.2016.11.001. [PMID: 28185757](#)
 20. Chapman BC, Hosokawa P, Henderson W, Paniccia A, Overbey DM, Messersmith W, **Lieu C**, Stiegmann GV, Schulick RD, Gajdos C. Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer. *J Surg Oncol* 2017 Mar 23. doi: 10.1002/jso.24613. [PMID: 28334436](#)
 21. Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, **Lieu CH**, Schefter TE, Goodman KA, Rusthoven CG. Adjuvant radiotherapy improves overall survival in resected gastric adenocarcinoma: a National Cancer Database analysis. *Cancer* 2017. Doi: 10.1002/cncr.30748. [PMID: 28513823](#)
 22. **Lieu CH**, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tshako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. *Oncologist* 2017; doi: 10.1634/theoncologist.2017-0175. [PMID: 28592615](#)
 23. Amini A, Jones BL, Stumpf P, Leong S, **Lieu CH**, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Schefter T, Goodman KA. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. *Pancreas* 2017. Aug;46(7):904-912. [PMID: 28697131](#)

24. Dotan E, Cohen SJ, Starodub AN, **Lieu CH**, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. *J Clin Oncol* 2017. Aug 17;JCO2017739011. doi: 10.1200/JCO.2017.73.9011. [PMID: 28817371](#)
25. D Sheneman, Finch JL, Davis SL, Leong S, Weekes CD, Purcell WT, Goodman KA, Messersmith WA, Eckhardt SG, **Lieu CH**. Incidence of colorectal cancer among young adults in the state of Colorado. *Colorectal Cancer* 2017. Nov;6(2): 49-59. doi:10.2217/crc-2017-0008.
26. Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Liaz LA, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, **Lieu CH**, Messersmith WA, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. A blueprint to advance colorectal cancer immunotherapies. *Cancer Immunol Res* 2017; 5(11): 42-949. [PMID: 29038296](#)
27. Goey KH, Sorbye H, Glimelius B, Adams RA, Andre T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Diaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, **Lieu CH**, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcborg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. *Eur J Cancer* 2018; 100:35-45. [PMID: 29936065](#)
28. Krishnamurthy A, Dasari A, Noonan AM, Mehnert J, Lockhart AC, Leong S, Capasso A, Stein M, Sanoff H, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, **Lieu CH**. A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). *Cancer Res* 2018; pii: canres.0316.2018. doi: 10.1158/0008-5472.CAN-18-0316. [PMID: 30042150](#)
29. Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, **Lieu CH**, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. *Oncologist* 2018; pii: theoncologist.2018-0315. doi: 10.1634/theoncologist.2018-0315. [Epub ahead of print]. [PMID: 30139840](#)
30. Emens LA, Davis SL, Oliver SCN, **Lieu CH**, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D. Association of cancer immunotherapy with acute macular neuroretinopathy and diffuse retinal venulitis. *JAMA Ophthalmol* 2018. doi: 10.1001/jamaophthalmol.2018.5191. [PMID: 30383154](#).
31. Capasso A, Lang J, Pitts TM, Jordan KR, **Lieu CH**, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. *J Immunother Cancer* 2019; 7(1): 37. doi: 10.1186/s40425-019-0518-z. [PMID: 30736857](#).
32. **Lieu C**, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruiz-Garcia E, You YN, Baxter N. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. *J Clin Oncol* 2019; JCO1900281. doi: 10.1200/JCO.19.00281. [Epub ahead of print]. [PMID: 30986117](#)
33. Dwyer AJ, Murphy CC, Boland CR, Garcia R, Hampel H, Limburg P, Lowery J, Zauber AG, Waring S, Worrall S, Perea J, Siegel R, Lee J, Molmenti C, Sears CL, Buckhaults P, Hayes R, Hussan H, de Miranda

- N, Palles C, Diaz L, Song M, Cercek A, **Lieu CH**, Patel SG, Karlitz JJ, Cao Y, Demb J, Blatchford P, Risendal B, Weltzien E, Wali A, Daschner P, Loomans-Kropp H, Flores R, Levell CL, Wehling K, Martin J, Pesmen C, Kuchar V, Soisson R, Davis A, Ahnen D. A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer. *Gastroenterology* 2019; S0016-5085(19):40882-2. [PMID: 31095950](#)
34. Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, **Lieu CH**, Golemis EA, Meyer JE. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. *Nature Communications* 2019; 10(3722). [PMID: 31427573](#)
35. **Lieu CH**, Golemis EA, Serebriiskii IG, Newberg JY, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton GM, Cooke M, Meyer JE. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. *Clin Can Res* 2019; doi: 10.1158/1078-0432.CCR-19-0899. [PMID: 31243121](#)
36. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, **Lieu CH**, Lenz HJ, Lindwasser W, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. *Nat Rev Clin Oncol* 2020; doi: 10.1038/s41571-020-0392-0. [PMID: 32632268](#)
37. Moroney JW, Powderly J, **Lieu CH**, Bendell JC, Eckhardt SG, Chang CW, Molinero L, Spahn J, Williams P, Lin YG, Hodi FS. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. *Clin Can Res* 2020; doi: 10.1158/1078-0432.CCR-20-0477. [PMID: 32723836](#)
38. Holowatyj AN, Washington KM, Salaria SN, **Lieu CH**, Idrees K, Eng C. Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. *Gastroenterology* 2020 Oct;159(4):1605-1608. doi: 10.1053/j.gastro.2020.06.011. Epub 2020 Jun 13. [PMID: 32540351](#)
39. Holowatyj A, Langston M, Han Y, Viskochil R, Perea J, Cao Y, Rogers C, **Lieu CH**, Moore JX. Community Health Behaviors and Geographic Variation in Early-Onset Colorectal Cancer Survival Among Women. *Clinical and Translational Gastroenterology* 2020; 11(12): e00266. doi: 10.14309/ctg.0000000000000266 [PMCID: PMC7678794](#)
40. Sandhu GS, Anders R, Blatchford P, Walde A, Leal A, King G, Leong S, Davis SL, Purcell WT, Goodman KA, Scheffer T, Cowan M, Herter W, Meguid C, Weiss R, Marsh M, Brown M, Vogel J, Birnbaum E, Ahrendt S, Gleisner A, Schulick R, Del Chiaro M, McCarter M, Patel SG, Messersmith WA, **Lieu CH**. High incidence of prolonged rectal bleeding and advanced stage cancer in early-onset colorectal cancer patients. *Colorectal Cancer* 2020; 9(3): doi.org/10.2217/crc-2020-0012
41. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, **Lieu CH**, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). *J Clin Oncol* 2020; doi: 10.1200/JCO.20.01994. [PMID: 33356422](#)
42. Kastelowitz N, Marsh MD, McCarter M, Meguid RA, Bhardwaj NW, Mitchell JD, Weyant MJ, Scott C, Scheffer T, Stumpf P, Leong S, Messersmith, **Lieu C**, Leal AD, Davis SL, Purcell WT, Kane M, Wani S, Shah R, Hammad H, Edmundowicz S, Goodman KA. Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. *Front Oncol* 2021; 11:614640. doi: 10.3389/fonc.2021.614640.

Invited Articles and Reviews: Peer-Reviewed

1. **Lieu C**, Anderson R. Serum creatinine: Why lower may not be better. *Crit Care Med* 2007; 35(10):2458-9. [PMID: 17885392](#)
2. **Lieu C**, Kopetz S. The Src family of protein kinases: a new and promising target for colorectal cancer. *Clin Colorectal Cancer* 2010; 9(2):89-94. [PMID: 20378502](#)
3. Journal Honors **Christopher Lieu, MD**, As Recipient of the 2010 JCO Young Investigator Award, *J Clin Oncol* 2010; 28(19):3099-3100. [PMID: 20516440](#)
4. **Lieu CH**, Heymach JV, Overman MJ, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. *Clin Cancer Res* 2011; 17(19): 6130-9. [PMID: 21953501](#)
5. Scott AJ, Leong S, Messersmith WA, **Lieu CH**. [A Moving Target: challenges in treating BRAF-mutant colorectal cancer](#). *Colorectal Cancer* 2013; 2(3): 197-204.
6. **Lieu CH**, Eckhardt SG. BRAF inhibition in colorectal cancer: From theoretical promise to challenging reality. *2013 ASCO Gastrointestinal Cancers Symposium Proceedings*. 58-59.
7. Brittain P, Eckhardt SG, **Lieu CH**. [Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer](#). *Current Cancer Therapy Reviews* 2014; 10(1):34-38.
8. Tai D, Wells K, Arcaroli J, Vanderbilt C, Aisner DL, Messersmith WA, **Lieu CH**. Targeting the WNT signaling pathway in cancer therapeutics. *The Oncologist* 2015; 20(10):1189-98. [PMID: 26306903](#). PMCID: PMC4591954
9. **Lieu CH**, Sorkin A, Messersmith WA. Right to Try? *J Clin Oncol* 2015; doi: 10.1200/JCO.2014.60.6004. [PMID: 25779561](#)
10. Scott A, **Lieu CH**, Messersmith WA. Therapeutic approaches to RAS mutation. *Cancer J*. 2016; 22(3): 165-74. [PMID: 27341593](#)
11. Friedrich T, Leong S, **Lieu CH**. Beyond RAS and BRAF: A target rich disease that is ripe for picking. *J Gastronintest Oncol* 2016; 7(5): 705-712. [PMID: 27747084](#) PMCID: PMC5056247
12. King GT, **Lieu CH**, Messersmith WA. Frontline strategies for metastatic colorectal cancer: new sides to the story. *Am J Hem Onc* 2016; 12(10): 4-11.
13. **Lieu CH**, Messersmith WA. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same. *JAMA* 2017;317(23):2376-2378. [PMID: 28632850](#)
14. McCanney J, Winckworth-Prejsnar K, Schatz AA, Nardi EA, Dwyer AJ, **Lieu C**, Biru Y, Carlson RW. Addressing Survivorship Care. *J Natl Compr Canc Netw* 2018; 16(7): 801-806. [PMID: 30006422](#)
15. Eckhardt SG, **Lieu CH**. Is precision medicine an oxymoron? *JAMA Oncol* 2018;5(2):142-143. doi: 10.1001/jamaoncol.2018.5099. [Epub ahead of print]. [PMID: 30419105](#)
16. **Lieu CH**, Corcoran RB, Overman MJ. Integrating biomarkers and targeted therapy into colorectal cancer management. *American Society of Clinical Oncology Educational Book* 2019; 39:207-215. [PMID: 31099678](#)
17. Friedrich T, **Lieu CH**. Selecting the Best Treatment Option for Patients with Microsatellite Instability–High Metastatic Colorectal Cancer. *ASCO Daily News* 2020. <https://dailynews.ascopubs.org/doi/10.1200/ADN.20.200348/full/>

Book Chapters

1. William WN, **Lieu CH**, Lippman S. Chemoprevention. In: Olshan AF, ed. *Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer*: Springer; 2010.

2. **Lieu C**, William WN, Lippman S. Chemoprevention Studies. In: Hidalgo M, Garrett-Mayer E, Clendeninn NJ, Eckhardt SG, eds. Principles of Anticancer Drug Development: Springer; 2010.
3. **Lieu C**, Fornier K, Overman M. Appendiceal Tumors. In: Kantarjian HM, Wolff RA, Koller CA, eds. MDACC Manual of Medical Oncology: McGraw-Hill; 2011.
4. **Lieu CH**, Eckhardt SG, Messersmith WA. Future Directions in the Treatment of Colorectal Cancers. In: Benson AB, Chakravarthy AB, Hamilton SR, Sigurdson ER, eds. Cancers of the Colon and Rectum – A Multidisciplinary Approach to Diagnosis and Management: Demos Medical Publishing; 2013.
5. Overman M, Raghav K, **Lieu CH**, Small Bowel Cancer and Appendiceal Tumors. In: Kantarjian HM, Wolff RA, Koller CA, eds. MDACC Manual of Medical Oncology: McGraw-Hill; 2016.
6. Kessler E, Davis SL, Brittain P, Leong S, Eckhardt SG, **Lieu CH**. Targeted Therapies. In: American Cancer Society Textbook of Cancer. 2017.
7. Reidy-Lagunes D, **Lieu CH**, Messersmith WA, Goodman K. Unusual Tumors of the Colon, Rectum, and Anus In: Blanke CD, Brown J, Kim ES, Reaman GH, Sekeres MA, eds. Textbook of Uncommon Cancer: John Wiley and Sons. 2017.
8. Azad N, **Lieu CH**. Colorectal and Anal Cancer. In: Issacs C, Agarwala SS, Cheson BD, Ma AD, Marshall JL, Rizvi NA, eds. Hoffman and Abeloff's Hematology-Oncology Review, 1e: Elsevier. 2018.

Original Research: Published Abstracts

1. **Lieu CH**, Leong S, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Boinpally R, Eckhardt SG, O'Bryant CL. A Dose-Ranging Study of the Toxicities, Pharmacological, and Biological Effects of the Selective Apoptotic Antineoplastic Drug (SAAND), OSI-461 in Patients With Advanced Cancer, in the Fasting and Fed State. *Clinical Cancer Research* 11:9103S.
2. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, **Lieu C**, Agarwal A, Maru D, Sieber O, Desai J. Distinct differences in sites of metastatic disease may contribute to poorer outcomes observed in patients with BRAF mutant colorectal cancers. *J Clin Oncol* 2010;28:15s (suppl; abstr 3592).
3. **Lieu C**, Wolff RA, Eng M, Overman M, Henry L, Coulson R, Garrett C, Abbruzzese J, Gallick G, Kopetz S. Phase IB Study of the Src Inhibitor Dasatinib with FOLFOX and Cetuximab in Metastatic Colorectal Cancer. *J Clin Oncol* 2010;28:15s (suppl; abstr 3536).
4. **Lieu C**, Tran H, Fiorentino S, Jiang Z, Mao M, Overman M, Eng C, Ellis L, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. *J Clin Oncol* 29: 2011 (suppl 4; abstr 401).
5. **Lieu CH**, Tran HT, Jiang, Z, Mao M, Overman MJ, Eng C, Morris J, Ellis LM, Heymach J, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. *J Clin Oncol* 29:2011 (suppl; abstr 3533).
6. Shah NN, **Lieu CH**, Ivan C, Overman MJ, Shimizu M, Morris J, Tran HT, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients. *J Clin Oncol* 30: 2012 (suppl 4; abstr 456).
7. Bowles DW, Diamond JR, Lam ET, Messersmith WA, Weekes CD, Leong S, Gore L, **Lieu CH**, Freas E, Ren C, Wilhelm F, Eckhardt SG. Phase I study of oral rigosertib in patients with advanced solid tumors. *J Clin Oncol* 30: 2012 (suppl; abstr 3017).
8. Chen ZY, **Lieu CH**, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong DS, Hoff P, Tran HT, Heymach J, Overman MJ, Kopetz S. Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer. *J Clin Oncol* 30: 2012 (suppl; abstr 3598).

9. **Lieu CH**, Varella-Garcia M, Xu LG, Zhi-Qin J, Eckhardt SG, Messersmith WA, Maru DM, Kopetz S. Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer. *J Clin Oncol* 30:2013 (suppl 34; abstr 402).
10. Lee MS, **Lieu CH**, Overman MJ, Eng C, Morris J, Jiang ZQ, Morelli M, Heymach J, Tran HT, Kopetz S. Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer. *J Clin Oncol* 32:2014 (suppl 3; abstr 452).
11. **Lieu CH**, Harb WA, Beeram M, Power L, Kearns JD, Nering R, Moyo VM, Wolf BB, Adjei AA. Phase I trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors. *J Clin Oncol* 32:5s: 2014 (suppl; abstr 2518).
12. You YN, Chang K, Chen K, Mehdizadeh A, Cuddy A, **Lieu CH**, Shaw KR, Sanchez EV, Eng C. Somatic mutations in young-onset colorectal cancer unrelated to hereditary syndromes: A comparative study using high-depth targeted exome sequencing. *J Clin Oncol* 33: 2015 (suppl 3; abstr 623).
13. Kopetz S, McDonough S, Morris VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, **Lieu CH**, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie K, Hochster HS. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). *J Clin Oncol* 33:2015 (suppl 3; abstr TPS790).
14. Bendell KC, Powderly JD, **Lieu CH**, Eckhardt SG, Hurwitz H, Hochster HS, Murphy JE, Funke RP, Rossi C, Wallin J, Waterkamp D, Pishvaian MJ. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). *J Clin Oncol* 33:2015 (suppl 3, abstr 704).
15. **Lieu CH**, Beeram M, Harb WA, Kearns JD, Sloss CM, Nering R, Adjei AA, Wolf BB. Safety, pharmacology, and preliminary clinical activity of MM-151: An oligoclonal anti-EGFR therapeutic in patients with cetuximab-resistant CRC and other refractory solid tumors. *J Clin Oncol* 33:2015 (suppl 3; abstr 647).
16. Pitts TM, Kim J, Tan AC, You N, Eng C, Eckhardt SG, **Lieu CH**. Emerging transcriptional landscape and putative therapeutic strategies in young patients with metastatic colorectal cancer. *J Clin Oncol* 33:2015 (suppl; abstr e14627).
17. Dotan E, Starodub A, Berlin J, **Lieu CH**, Guarino MJ, Marshall J, Hecht JR, Cohen SJ, Messersmith WA, Maliakal PP, Wegener WA, Sharkey RM, Goldenberg DM. A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study. *J Clin Oncol* 33:2015 (suppl; abstr 2505).
18. Jain SK, Meguid C, Leong S, Edil BH, McCatter M, Schefter TE, Schulick R, **Lieu CH**. Multidisciplinary management of pancreatic adenocarcinoma with isolated pulmonary metastases. *J Clin Oncol* 34, 2016 (suppl 4S; abstr 384).
19. **Lieu CH**, Pitts TM, Kim J, Tan AC, Messersmith WA, You NY, Eng C, Eckhardt SG. Emerging transcriptional landscape and putative therapeutic targets in young patients with metastatic colorectal cancer (CRC). *J Clin Oncol* 34, 2016 (suppl 4S; abstr 605).
20. **Lieu CH**, Sheneman D, Finch JL, Davis SL, Leong S, Weekes CD, Purcell WT, Goodman KA, Messersmith WA, Eckhardt SG. Incidence of colorectal cancer among young adults in the state of Colorado. *J Clin Oncol* 34, 2016 (suppl; abstr 3585).
21. **Lieu CH**, Golemis E, Kim Jihye, Serebriiskii I, Bailey M, Tan AC, Pitts TM, Eng C, Ennis R, Eckhardt SG, Frampton GM, Meyer JE. Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer. *J Clin Oncol* 34, 2016 (suppl; abstr 3589).
22. Harb WA, Adjei AA, Beeram M, Pipas JM, Chen S, Valencia A, Rimkunas V, McClure T, Kearns JD, Nering R, **Lieu CH**. Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of

- MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors. *J Clin Oncol* 34, 2016 (supple; abstr 2518).
23. Kopetz S, McDonough SL, Morris VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Wang SE, **Lieu CH**, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie KA, Hochster HS. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). *J Clin Oncol* 35, 2017 (suppl 4S; abstract 520).
 24. Capasso A, Pitts TM, Tentler JJ, Klauck PJ, Bagby SM, Nguyen A, Arcaroli J, Cattaruzza F, Meyer JE, Connelly C, Eckhardt SG, **Lieu CH**. Rational combination therapy in young vs older patients with advanced colorectal cancer (CRC). *J Clin Oncol* 35, 2017 (suppl 4S; abstract 612).
 25. Krishnamurthy A, Dasari A, Lockhart AC, Stein MN, Sanoff HK, Lee JJ, Hansen AR, Bekaii-Saab TS, Malhotra U, Rippke S, Davis SL, Messersmith WA, Yao JC, Meric-Bernstam F, Eckhardt SG, **Lieu CH**. A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). *J Clin Oncol* 35, 2017 (suppl 4S; abstract 609).
 26. Connelly CF, Severson EA, **Lieu CH**, Meyer JE, Stephens P, Frampton GM. The age specific genomic landscape of cancer. *J Clin Oncol* 35, 2017 (suppl; abstr 1568).
 27. Capasso A, Lang J, Pitts TM, Francoeur P, Davis SL, **Lieu CH**, Bagby SM, Tentler JJ, Piscopio AD, Diamond JR, Pelanda R, Eckhardt SG. HDAC and PD-1 inhibition in humanized triple-negative breast cancer xenografts. *J Clin Oncol* 35, 2017 (suppl; abstr e14604).
 28. Burris HA, Gordon MS, Hellman MD, LoRusso P, Emens LA, Hodi FS, **Lieu CH**, Infante JR, Tsai FY, Elder JP, Cleary JM, Kelovac D, Tshako AL, Mueller L, Lin R, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. *J Clin Oncol* 35, 2017 (suppl; abstr 105).
 29. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Stein, MN, Sanoff HK, Lee JJ, Hansen AR, Bekaii-Saab TS, Malhotra U, Rippke S, Davis SL, Messersmith WA, Eckhardt SG, **Lieu CH**. A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). *J Clin Oncol* 35, 2017 (suppl; abstr 2587).
 30. Sinicrope FA, Ou FS, Shi Qian, Nixon AB, Levasseur A, Dueck AC, Dhanarajan AR, **Lieu CH**, Cohen DJ, Innocenti F, Behrens RJ, Peters W, Sargent DJ, Sommer N, O'Reilly EM, Meyerhardt J. Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502). *J Clin Oncol* 35, 2017 (suppl; abstr TPS3630).
 31. Kopetz S, McDonough SL, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Raghav KP, Morris VK, Wang SE, **Lieu CH**, Guthrie KA, Hochster HS. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). *J Clin Oncol* 35, 2017 (suppl; abstr 3505).
 32. Iyer P, Wong K, **Lieu CH**, Henry J, Davis SL, Goodman KA, Davies K, Aisner D, Messersmith WA, Leong S. Clinical and molecular characteristics of younger versus older patients with colorectal cancer. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 630).
 33. Henry J, Iyer P, Garberich R, Davis SL, **Lieu CH**, Meguid CL, Edil BH, Leong S. Ampullary adenocarcinoma: A single center experience. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 462).
 34. Cuny CJ, Hoyle J, O'Bryant CL, Meguid CL, **Lieu CH**, Davis SL, Messersmith WA, Leong S. A retrospective review of borderline resectable-locally advanced pancreatic adenocarcinoma (BR-LAPC) undergoing neoadjuvant chemotherapy followed by stereotactic body radiation therapy (SBRT) at the University of Colorado Cancer Center. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 436).

35. Friedrich T, Goodman KA, Leong S, Herter W, Davis SL, Vogel J, Gleisner A, Meguid CL, Purcell WT, McCarter M, Cowan M, Scheffter TE, Messersmith WA, **Lieu CH**. Early outcomes in patients with locally advanced rectal cancer following total neoadjuvant therapy. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 848).
36. Krishnamurthy A; Head LS; Weiss RE; Meguid C; Davis SL; Leong S; Messersmith WA.; Purcell WT; Leal A; Goodman KA; Johnson T; Brown M; Boniface M; Herter W; Edil B, Schulick R; McCarter M; Ahrendt S; **Lieu CH**. Impact of multidisciplinary management in the diagnosis and treatment of neuroendocrine tumors. *J Clin Oncol* 36, 2018 (suppl; abstr e16165)
37. Kasi PM, Dayyani F, Morris VK, Kopetz S, Parikh AR, Starr JS, Cohen S, Grothey A, **Lieu CH**, O'Hara MH, Loranger K, Westbrook L, Sharma S, Krinshpun S, Hook N, Zimmermann B, Billings PR, Aleshin A. Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced-stage colorectal cancer (CRC-MRD Consortia). *J Clin Oncol* 38: 2020 (suppl; abstr 4108)
38. **Lieu CH**, Davis SL, Leong S, Leal AD, Blatchford PJ, Sandhu GS, Purcell WT, Kim SS, Van de Voorde Z, Telles R, Martin A, Cull T, Waring M, Reed C, Lee C, Siedem A, Lee MR, Pitts T, Eckhardt SG, Messersmith WA. Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC). *J Clin Oncol* 38: 2020 (suppl; abstr 4031)

Original Research: Oral Abstract Presentations at National/International Meetings

1. **Lieu CH**, Renfro L, de Gramont A, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent D, Eckhardt SG, Eng C. The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program. The European Cancer Congress 2013. Amsterdam, NE.
2. **Lieu CH**, Bendell J, Powderly J, Pishvaian M, Hochster H, Eckhardt SG, Funke R, Rossi C, Waterkamp D, Hurwitz JH. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or solid tumors. European Society of Medical Oncology Annual Meeting 2014. Madrid, Spain.
3. **Lieu CH**, Pitts TM, Capasso A, Spreafico A, Eckhardt SG. A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer. *Conquer Cancer Foundation Scientific and Career Development Retreat*. Alexandria, VA. October 16, 2015.

Original Research: Published Abstract Presentations at National/International Meetings

1. **Lieu C**, Lambert L, Wolff RA, Eng C, Lin E, Rafeeq S, Fournier K, Royal R, Mansfield P, Overman MJ. The role of surgical cytoreduction and systemic chemotherapy in metastatic poorly differentiated or signet ring cell adenocarcinomas of the appendix. In: 2010 Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando, FL: Abstract ID 479.
2. **Lieu C**, Wolff RA, Eng M, Overman M, Henry L, Coulson R, Garrett C, Abbruzzese J, Gallick G, Kopetz S. Phase IB Study of the Src Inhibitor Dasatinib with FOLFOX and Cetuximab in Metastatic Colorectal Cancer. In: 2010 Symposia on Cancer Research; 2010 Oct 8-9; Houston, TX: Abstract D4.
3. **Lieu CH**, Tentler JJ, Tan AC, Pitts TM, Spreafico A, Selby HM, McPhillips KL, Bagby SM, Eckhardt SG. TAK-733, and investigational novel MEK inhibitor, suppresses colorectal cancer (CRC) tumor growth in biomarker positive patient-derived human tumor explants. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2012 Nov 6-9; Dublin, Ireland: Abstract 393.
4. Dotan E, Cohn SJ, Starodub AN, **Lieu CH**, Messersmith WA, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Maliakal P, Wegener WA, Sharkey RM, Wilhelm F, Lee L, Goldenberg DM, Berlin JD. Labetuzumab

govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results. 2016 AACR Annual Meeting. Abstract# CT065.

5. Wallin J, Pishvaian MJ, Hernandez G, Yadav M, Jhunjunwala S, Delamarre L, He X, Powderly J, **Lieu CH**, Eckhardt SG, Hurwitz H, Hochster HS, Murphy J, Leveque V, Cha E, Funke R, Waterkamp D, Hegde P, Bendell J. Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma. 2016 AACR Annual Meeting. Abstract# 2651
6. Capasso A, Dasari A, Lockhart AC, Stein M, Sanoff H, Lee J, Hansen A, Bekaii-Saab T, Rippke S, Yao J, Meric-Bernstam F, Eckhardt SG, **Lieu CH**. A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). 2016 AACR Annual Meeting. Abstract# CT146.

Patient Education Materials

1. Biomarkers and Testing. Fight CRC Patient Information Packet 2017.

Original Research: Protocols

- Protocol: 2010-0378 – Bristol-Myers Squibb
Title: Phase II study of second-line irinotecan plus brivanib, a dual tyrosine inhibitor of VEGF and FGFR, in metastatic colorectal cancer patients enriched for elevated levels of plasma bFGF following progression on bevacizumab treatment
Role: Co-Principal Investigator: Christopher Lieu, M.D., Principal Investigator: Michael J. Overman, M.D.
- Protocol: COMIRB# 11-134 – Merrimack
Title: A phase I and pharmacologic study of MM-151 in patients with refractory advanced solid tumors
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 12-25 – Novartis
Title: A randomized, double-blind, multicenter, phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin (RADIANT-4)
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 13-0395 – Novartis
Title: Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 13-2486 – Immunomedics
Title: A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: NCI Protocol# 9571 – COMIRB 13-2628
Title: A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (selumetinib) and Cyclosporin A (CsA) in Patients with Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
Role: Principal Investigator: Christopher Lieu, M.D.

- Protocol: NCI/CTEP/IDB/DCTD Protocol# EAY131
Title: Molecular Analysis for Therapy Choice (MATCH) – Phase 2 study of crizotinib in patients with tumors (other than adenocarcinoma of lung) with ROS1 translocation
Role: co-Principal Investigator: Christopher Lieu, M.D., Study Chairs: Keith Flaherty, Alice Chen
- Protocol: COMIRB# 15-0802 – Novartis
Title: A phase II, multicenter, single-arm study of oral ceritinib in adult patients with ALK-activated gastrointestinal malignancies
Role: Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 15-1205 – Merrimack
Title: A phase 1 study evaluating the safety, pharmacology, and preliminary activity of the co-administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 15-2031 – Ipsen
Title: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 16-0991 – Array
Title: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 16-0989 – Genentech
Title: A phase IB open-label study evaluating the safety, tolerability and pharmacokinetics of cobimetinib in combination with bevacizumab and immunotherapy when administered in patients with gastrointestinal and other tumors
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 17-7807 – Roche
Title: An open-label, multicenter, dose-escalation phase I study to evaluate the safety, pharmacokinetics, and therapeutic activity of RO6958688, a novel t-cell bispecific antibody that targets the human carcinoembryonic antigen (CEA) on tumor cells and CD3 of T-cells, administered intravenously in patients with locally-advanced and/or metastatic CEA(+) solid tumors.
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 17-0466 – University of Colorado (Investigator-Initiated Trial)
Title: Phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory colorectal cancer
Role: Study Principal Investigator
- Protocol: COMIRB# 17-1021 – Merck
Title: Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Role: Local Principal Investigator: Christopher Lieu, M.D.
- Protocol: COMIRB# 17-2036 – National Clinical Trials Network

Title: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
 Role: SWOG Principal Investigator

Protocol: COMIRB# 18-1672 – Inhibrx
 Title: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
 Role: Local Principal Investigator: Christopher Lieu, M.D.

Protocol: COMIRB# 18-1721 – Holy Stone
 Title: Phase 1, Two-Part (Dose Escalation, Dose Expansion), Multicenter, Non-Randomized, Open-Label, Multiple Dose, First-in-Human Study of CA102N Monotherapy and of CA102N combined with Trifluridine/Tipiracil (LONSURF) in Subjects with Advanced Solid Tumors
 Role: Local Principal Investigator: Christopher Lieu, M.D.

Protocol: COMIRB# 19-3118 – ST Pharm
 Title: First-In-Human Dose-Escalation Study of STP1002 in Patients with Advanced-Stage Solid Tumors
 Role: Local Principal Investigator: Christopher Lieu, M.D.

Protocol: COMIRB# 20-1267 – Daiichi-Sankyo
 Title: A multi-center, open-label, phase 2 study to evaluate safety and efficacy of U3-1402 in subjects with advanced or metastatic colorectal cancer
 Role: Local Principal Investigator: Christopher Lieu, M.D.

INTERNATIONAL SCIENTIFIC MEETINGS ATTENDED

Oct. 2012 Southwest Oncology Group (SWOG) Fall Meeting. Chicago, IL, (CME designated activity)

Jan. 2013 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA (CME designated activity)

May 2013 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, (CME designated activity)

Sept. 2013 European Society for Medical Oncology (ESMO). Amsterdam, Netherlands, (CME designated activity)

Oct. 2013 Southwest Oncology Group (SWOG) Fall Meeting. Chicago, IL, (CME designated activity)

Jan. 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA (CME designated activity)

Feb. 2014 American Association for Cancer Research (AACR) RAS Targets Meeting. Orlando, FL, (CME designated activity)

April 2014 American Association for Cancer Research (AACR) Annual Meeting. San Diego, CA, (CME designated activity)

May 2014 Southwest Oncology Group (SWOG) Spring Meeting. San Francisco, CA, (CME designated activity)

Sept. 2014 European Society for Medical Oncology (ESMO). Madrid, Spain (CME designated activity)

Oct. 2014 Southwest Oncology Group (SWOG) Fall Meeting. Chicago, IL, (CME designated activity)

Jan. 2015 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA, (CME designated activity)

- April 2015 American Association for Cancer Research (AACR) Annual Meeting. Washington DC, (CME designated activity)
- April 2015 Southwest Oncology Group (SWOG) Spring Meeting. San Francisco, CA, (CME designated activity)
- May 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, (CME designated activity)
- Oct. 2015 Southwest Oncology Group (SWOG) Fall Meeting. Chicago, IL, (CME designated activity)
- Nov. 2015 American Association for Cancer Research (AACR). Boston, MA, (CME designated activity)
- Jan. 2016 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA (CME designated activity)
- April 2016 American Association for Cancer Research (AACR) Annual Meeting. New Orleans, LA, (CME designated activity)
- May 2016 Southwest Oncology Group (SWOG) Spring Meeting. San Francisco, CA, (CME designated activity)
- June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, (CME designated activity)
- Sept. 2016 Southwest Oncology Group (SWOG) Fall Meeting. Chicago, IL, (CME designated activity)
- Sept. 2016 Cancer Therapy Evaluation Program (CTEP) Early Drug Development Meeting. Washington DC,
- January 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA (CME designated activity)
- April 2017 American Association for Cancer Research (AACR) Annual Meeting. Washington DC, (CME designated activity)
- May 2017 Southwest Oncology Group (SWOG) Spring Meeting. San Francisco, CA, (CME designated activity)
- June 2017 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL (CME designated activity)
- October 2017 Southwest Oncology Group (SWOG) Fall Meeting. Chicago, IL (CME designated activity)
- January 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA (CME designated activity)
- June 2018 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL (CME designated activity)
- January 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA (CME designated activity)
- June 2019 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL (CME designated activity)
- June 2020 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL (CME designated activity)
- January 2021 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Virtual Meeting (CME designated activity)